Cargando…

Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates

SIMPLE SUMMARY: Skeletal muscle depletion is one of the established prognostic factors for hepatocellular carcinoma (HCC). This study clearly demonstrated that skeletal muscle mass continued to decrease significantly during lenvatinib (LEN) or sorafenib (SOR) treatment, which has recently played a m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imai, Kenji, Takai, Koji, Unome, Shinji, Miwa, Takao, Hanai, Tatsunori, Suetsugu, Atsushi, Shimizu, Masahito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486953/ https://www.ncbi.nlm.nih.gov/pubmed/37686497 http://dx.doi.org/10.3390/cancers15174223

Ejemplares similares

FIB‑4 index and NAFLD fibrosis score are useful indicators for screening high‑risk groups of non‑viral hepatocellular carcinoma
por: Imai, Kenji, et al.
Publicado: (2023)

Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Imai, Kenji, et al.
Publicado: (2019)

Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma
por: Imai, Kenji, et al.
Publicado: (2020)

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Imai, Kenji, et al.
Publicado: (2015)

Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report
por: Miwa, Takao, et al.
Publicado: (2021)

Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma
por: Unome, Shinji, et al.
Publicado: (2022)

Increased Visceral Adipose Tissue and Hyperinsulinemia Raise the Risk for Recurrence of Non-B Non-C Hepatocellular Carcinoma after Curative Treatment
por: Imai, Kenji, et al.
Publicado: (2021)

Higher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic Livers
por: Imai, Kenji, et al.
Publicado: (2021)

Effect of Selenium Deficiency on the Development of Overt Hepatic Encephalopathy in Patients with Chronic Liver Disease
por: Nakahata, Yuki, et al.
Publicado: (2023)

Prevalence, association, and prognostic significance of polypharmacy and sarcopenia in patients with liver cirrhosis
por: Hanai, Tatsunori, et al.
Publicado: (2023)

Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle Volume
por: Imai, Kenji, et al.
Publicado: (2017)

Usefulness of the Trabecular Bone Score in Assessing the Risk of Vertebral Fractures in Patients with Cirrhosis
por: Ogiso, Yui, et al.
Publicado: (2022)

Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment
por: Imai, Kenji, et al.
Publicado: (2019)

Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment
por: Imai, Kenji, et al.
Publicado: (2020)

Late Evening Snack with Branched-Chain Amino Acids Supplementation Improves Survival in Patients with Cirrhosis
por: Hanai, Tatsunori, et al.
Publicado: (2020)

Usefulness of the Stroop Test in Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy
por: Hanai, Tatsunori, et al.
Publicado: (2021)

A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis
por: Miwa, Takao, et al.
Publicado: (2022)

Association between Body Composition and the Risk of Portopulmonary Hypertension Assessed by Computed Tomography in Patients with Liver Cirrhosis
por: Miwa, Takao, et al.
Publicado: (2023)

Increased visceral fat volume raises the risk for recurrence of hepatocellular carcinoma after curative treatment
por: Imai, Kenji, et al.
Publicado: (2018)

Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review
por: Sakai, Hiroyasu, et al.
Publicado: (2020)

Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis
por: Hanai, Tatsunori, et al.
Publicado: (2020)

Effects of Rifaximin on Circulating Albumin Structures and Serum Ammonia Levels in Patients with Liver Cirrhosis: A Preliminary Study
por: Miwa, Takao, et al.
Publicado: (2022)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Mac-2-binding protein glycosylation isomer is useful to predict muscle cramps in patients with chronic liver disease
por: Miwa, Takao, et al.
Publicado: (2022)

Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma
por: Briggs, Andrew, et al.
Publicado: (2020)

Impact of Serum Chemerin Levels on Liver Functional Reserves and Platelet Counts in Patients with Hepatocellular Carcinoma
por: Imai, Kenji, et al.
Publicado: (2014)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
por: Kim, Soo Young, et al.
Publicado: (2018)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
por: Cui, Yanjun, et al.
Publicado: (2022)

Idiopathic Ileocolonic Varices Coexisting with a Colon Polyp Treated Successfully by Endoscopy: A Case Report and Literature Review
por: Miwa, Takao, et al.
Publicado: (2019)

Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis
por: Guan, Jun, et al.
Publicado: (2021)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020)

Usefulness of health checkup for screening metabolic dysfunction-associated fatty liver disease and alcohol-related liver disease in Japanese male young adults
por: Tajirika, Satoko, et al.
Publicado: (2023)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis
por: Shimizu, Masahito, et al.
Publicado: (2012)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment
por: Watanabe, Naoki, et al.
Publicado: (2011)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

NEAT1–SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines
por: Tsuchiya, Hiroyuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_82jej2ifl4s3vgad4jqhhfinr7